兴科蓉医药（股票代码：06833）于2026年4月1日披露了截至2026年3月31日的股份变动月报表。根据公告，公司法定（注册）股本仍为10,000,000,000股，面值为每股0.0001港元，总额1,000,000港元；已发行股份总数2,032,890,585股，报告期内未发生增发、购回、注销及库藏股变化。
公司提示，其已于2025年5月26日采纳并生效的购股权计划在本月内授出、行使及失效数量均为零，目前可能透过该计划发行的股份数目为203,289,058股，截至3月末并未因此产生任何新增发行。
公告显示，公司确认截至本月末，已满足香港联交所《上市规则》下的公众持股量要求，整体股本结构保持稳定。有关月报表由公司董事会主席黄祥彬签署，兴科蓉医药重申将持续遵守相关法律规定及香港联交所《上市规则》的要求。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.